Skip to main
BNGO
BNGO logo

Bionano Genomics (BNGO) Stock Forecast & Price Target

Bionano Genomics (BNGO) Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 67%
Buy 0%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

Bionano Genomics demonstrated a robust 17% year-over-year increase in the sale of nanochannel array flowcells, with sales reaching 7,233 in 2Q25 compared to 6,165 in 2Q24. Additionally, the company reported a combined revenue increase of 11% year-over-year for consumables, software, and other services in 2Q25, with notable growth of 16% in consumables and software revenue. Furthermore, Bionano increased its expectations for new optical genome mapping (OGM) installations in FY2025, projecting a range of 20-25, an improvement from the previous forecast of 15-20 installations.

Bears say

Bionano Genomics Inc faces a negative outlook primarily due to several operational and financial risks, including lower-than-expected market uptake of its products and reduced utilization of installed systems. Projections suggest a conservative EV/Revenue multiple of 1.2x based on a sales forecast of $6.50 per share, coupled with a net cash position of $3.28 per share, indicates potential challenges in achieving the projected price objective of approximately $11. Additionally, the company may grapple with difficulties in securing additional capital needed for operations, enhancing concerns regarding dilution risk for existing shareholders.

Bionano Genomics (BNGO) has been analyzed by 3 analysts, with a consensus rating of Buy. 67% of analysts recommend a Strong Buy, 0% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Bionano Genomics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Bionano Genomics (BNGO) Forecast

Analysts have given Bionano Genomics (BNGO) a Buy based on their latest research and market trends.

According to 3 analysts, Bionano Genomics (BNGO) has a Buy consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Bionano Genomics (BNGO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.